MediBIC Group ^Investors

MediBIC Group is a leading biotechnology company in Japan specializing in Pharmacogenomics (PGx). Their main goal is to deliver a health care platform optimized for each individual. They achieve this by providing project planning, IRB, and data analysis services to support drug discovery and development for personalized medicine. MediBIC Group has achieved significant milestones in their research, including successful clinical trials for various types of cancer, such as breast cancer, non-small cell lung cancer, and pancreatic cancer. Their innovative approach has shown promising results in tumor reduction and has the potential to revolutionize cancer treatment.